CYV Ceryvyn Therapeutics Limited
Healthcare · Biotechnology
· website
$0.01
52wk 0.01 – 0.60
Overall
41.8
Value
83.8
Growth
0.0
Health
69.2
Quality
34.8
Momentum
11.9
Dividend
—
Price
About Ceryvyn Therapeutics Limited
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 22.2% |
| 1 month | 0.0% |
| 3 months | -21.4% |
| 6 months | -98.2% |
| 1 year | -98.2% |
| 3 years | -96.7% |
Risk
| Volatility (1y ann.) | 115.6% |
| Beta vs ASX 200 | -0.49 |
| Sharpe (1y) | -1.03 |
| VaR 95% (1-day) | -8.3% |
| Max drawdown (1y) | -98.5% |
| Off 1-year high | -98.2% |
Technicals
| RSI(14) | 60 |
| vs 50DMA | 1.2% |
| vs 200DMA | -96.8% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
83.8
Trailing P/E
100
Forward P/E
—
PEG ratio
94
EV / EBITDA
100
Price / Book
100
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
0
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
69.2
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
34.8
Return on equity
—
Return on assets
0
Operating margin
0
Net margin
100
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
11.9
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
56
Position in 52-week range
0
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$15.05M
P/E (trailing)
0.05
P/E (forward)
—
EPS (trailing)
0.24
Dividend yield
—
Payout ratio
0.0%
Beta
1.49
EV / EBITDA
1.25
Price / Book
0.50
ROE
—
Operating margin
-1,194,700.0%
Net margin
33,044,500.0%
Total cash
$30.02M
Total debt
$0
Current ratio
13.78
Debt / Equity
—
Free cash flow
$-16.21M
Avg volume
5.67M
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$1.00K
- Gross profit—
- Operating income-$11.95M
- Net income$330.44M
- Diluted EPS—
- Free cash flow-$12.50M
- Net debt-$30.02M